CEACAM5 and colorectal carcinoma: In addition, serum miR-139-3p showed high AUC and sensitivities in both early and late stage CRCs and CRCs at proximal and distal locations, thus serum miR-139-3p is able to compensate the limitation of sigmoidoscopy and FOBT that show lower sensitivity for proximal CRC [13] and some blood-based biomarkers, for example, blood CEA that show lower sensitivity for early stage CRC [14].